In a patient with neurofibromatosis who previously had a right adrenalectomy for pheochromocytoma and now shows left adrenal thickening on CT with isolated elevation of 24‑hour urinary dopamine while norepinephrine, epinephrine and metanephrines are normal, how should this be managed?

Management of Isolated Urinary Dopamine Elevation with Left Adrenal Thickening in NF1 Patient

This patient requires functional imaging with FDOPA-PET and should proceed to adrenalectomy given the high likelihood of a dopamine-secreting pheochromocytoma, which carries increased malignancy risk and can be metanephrine-negative. 1

Biochemical Interpretation

• Isolated dopamine elevation is highly suspicious for pheochromocytoma in NF1 patients, despite normal metanephrines and other catecholamines 1, 2
• Dopamine-secreting pheochromocytomas are rare but well-documented in NF1, representing tumors with immature catecholamine synthesis that fail to convert dopamine to norepinephrine 2
• Plasma free metanephrines are the most sensitive screening test for typical pheochromocytomas in NF1, but dopamine-secreting tumors can be metanephrine-negative 3, 4
• Measurement of methoxytyramine (the O-methylated metabolite of dopamine) would be ideal if available, as it helps detect dopamine-only producing tumors 4, 5

Functional Imaging Strategy

• FDOPA-PET is superior to MIBG scintigraphy for detecting pheochromocytomas in hereditary syndromes like NF1 3, 1
• In the documented NF1 case with dopamine-secreting pheochromocytoma, FDOPA-PET showed significant uptake and helped guide surgical decision-making when tumor size increased 1
• MIBG may show uptake but FDOPA-PET provides better sensitivity for these tumors 3, 1

Surgical Indications

Adrenalectomy is indicated for pheochromocytomas in NF1 patients, and minimally invasive surgery should be performed when feasible 3

Key considerations supporting surgery in this case:

• History of contralateral pheochromocytoma increases risk of recurrence (20% of NF1 pheochromocytomas are multifocal) 3
• Dopamine-secreting pheochromocytomas have higher malignancy potential than typical adrenergic/noradrenergic phenotypes 6
• Left adrenal thickening on CT with biochemical evidence of catecholamine production warrants removal 3
• 12% of NF1-associated pheochromocytomas are malignant, similar to sporadic disease 3

Critical Preoperative Management Considerations

Alpha-adrenergic blockade may NOT be appropriate for dopamine-secreting pheochromocytomas and can cause problematic hypotension and cardiovascular complications 6

• Consider calcium channel blockers or metyrosine as safer alternatives for preoperative preparation 6
• NF1-associated pheochromocytomas are more hemodynamically labile and dangerous during surgery, requiring extensive multidisciplinary coordination between endocrinology, anesthesia, and surgery 7
• Expect significant intraoperative blood pressure fluctuations; anesthesia team must be prepared for rapid hypertensive emergencies 7

Surveillance After Surgery

• Annual surveillance with plasma metanephrines is required long-term after pheochromocytoma resection in NF1 patients 3
• Include dopamine or methoxytyramine measurements given this patient's phenotype 4, 5
• Repeat functional imaging if biochemical recurrence is detected 3

Genetic Testing Considerations

• While this patient has known NF1, consider testing for SDHB and SDHD mutations if not already done, as these are associated with dopamine-secreting tumors 6, 5
• 70% of patients with SDHB/SDHD mutations show increased methoxytyramine (dopamine metabolite), distinguishing them from VHL-associated tumors 5